Noradrenergic Drugs Improve Cognition, Apathy in Alzheimer Disease
Researchers sought to evaluate the efficacy of noradrenergic drugs in the improvement of neuropsychiatric and cognitive symptoms in individuals with AD.
Researchers sought to evaluate the efficacy of noradrenergic drugs in the improvement of neuropsychiatric and cognitive symptoms in individuals with AD.
Ines Moreno-Gonzalez, PhD, an adjunct associate professor of neurology, explains healthy aging can help reduce lifestyle risk factors for Alzheimer disease.
In a retrospective study, researchers assessed the predictive value or serum lipid profiles on the basis of gender and hypermetabolism in patients with ALS.
Researchers sought to compare various high-caloric food supplements as add-on therapy to normal food intake and standard treatment in patients with ALS.
Researchers sought to develop a “roadmap” to early intervention and disease prevention for ALS by observing advances in neurodegenerative diseases with a presymptomatic period.
Researchers shared their findings on the relationship between metabolic factors, like blood markers of lipid and carbohydrate metabolism, and the risk of developing amyotrophic lateral sclerosis.
A team of researchers assessed COVID-19 outcomes in patients with neurodegenerative diseases compared with patients without such disease.